With 63% ownership of the shares, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is heavily dominated by institutional owners
Key Insights Given the large stake in the stock by institutions, Iovance Biotherapeutics' stock price might be...
Stay updated with breaking news from Wayne Rothbaum. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Key Insights Given the large stake in the stock by institutions, Iovance Biotherapeutics' stock price might be...
The stock markets generate an immense flood of raw data, a glut of information that presents a barrier to the average investor. How to sort through it, to find the right stocks to buy? What’s needed is some clear signal, something that can find some sensible patter in the results of millions of daily stock transactions. Fortunately, there are plenty of such signals out there. Purchases from the corporate insiders are generally seen as one of the clearest. The reason is simple. Corporate insiders
In an exclusive excerpt from For Blood And Money, the untold story of Wayne Rothbaum and the worst trade of his life. But what cost him some $700 million turned out to be the boon for countless cancer patients.
Iovance Biotherapeutics, Inc. (IOVA) shares are gaining more than 12 percent on Monday morning trade on reports that its independent director Wayne Rothbaum bought 28 percent more shares at an average price of $5.
The company's stock rally began on Friday.